An experimental vaccine against Alzheimer’s disease has cleared its first
hurdle. Elan Pharmaceuticals of Dublin announced this week that the first 100
patients to receive the vaccine had not suffered any serious side effects. Some
showed an immune response. Codenamed AN-1792, the vaccine is a synthetic version
of the amyloid protein that clogs up the brains of patients. The company now
plans to test the vaccine in the US and Europe.
To continue reading, today with our introductory offers
Advertisement
More from New Scientist
Explore the latest news, articles and features
Popular articles
Trending New Scientist articles
1
The world's fastest spider tops 3.5 metres per second
2
Babies are born with the neural foundations for maths
3
Where, when and how to watch the 2026 solar eclipse
4
I’m the first person whose life was saved by CRISPR base editing
5
Our verdict on The Selfish Gene: An unpopular piece of popular science
6
We’ve uncovered a master gene that switches on human development
7
Humans sleep the least of all apes – is it the secret to our success?
8
Remote-controlled cockroach swarm can now breathe underwater
9
US government wants to have a useful quantum computer by 2028
10
The most detailed survey of the universe ever conducted starts now
